119 related articles for article (PubMed ID: 38669353)
1. Defining Primary Refractory Large B-cell Lymphoma.
Bock AM; Mwangi R; Wang Y; Khurana A; Maurer MJ; Ayers A; Kahl BS; Martin P; Cohen JB; Casulo C; Lossos IS; Farooq U; Ayyappan S; Reicks TW; Habermann TM; Witzig TE; Flowers CR; Cerhan JR; Nastoupil LJ; Nowakowski GS
Blood Adv; 2024 Apr; ():. PubMed ID: 38669353
[TBL] [Abstract][Full Text] [Related]
2. Outcomes in refractory diffuse large B-cell lymphoma: results from a multicenter real-world study in China.
Wang S; Wang L; Hu J; Qian W; Zhang X; Hu Y; Zhu Q; Chen B; Wu D; Chang CH; Xu P; Zheng X; Wei J; Liu Y; Cui G; Tang Y; Ma Y; Huang H; Yi H; Zhao W
Cancer Commun (Lond); 2021 Mar; 41(3):229-239. PubMed ID: 33482051
[TBL] [Abstract][Full Text] [Related]
3. Refractory diffuse large B-cell lymphoma after first-line immuno-CT: Treatment options and outcomes.
Filliatre-Clement L; Maucort-Boulch D; Bourbon E; Karlin L; Safar V; Bachy E; Sesques P; Ferrant E; Bouafia F; Lazareth A; Ghergus D; Coiffier B; Traverse Glehen A; Salles G; Ghesquieres H; Sarkozy C
Hematol Oncol; 2018 May; ():. PubMed ID: 29722049
[TBL] [Abstract][Full Text] [Related]
4. Progression-Free Survival at 24 Months as A Landmark After Autologous Stem Cell Transplant in Relapsed or Refractory Diffuse Large B-cell Lymphoma.
Tun AM; Maliske S; Wang Y; Inwards DJ; Habermann TM; Micallef I; Porrata L; Paludo J; Bisneto JV; Rosenthal A; Kharfan-Dabaja MA; Ansell SM; Nowakowski GS; Farooq U; Johnston PB
Transplant Cell Ther; 2022 Sep; 28(9):610-617. PubMed ID: 35752441
[TBL] [Abstract][Full Text] [Related]
5. Impact of
Shouval R; Alarcon Tomas A; Fein JA; Flynn JR; Markovits E; Mayer S; Olaide Afuye A; Alperovich A; Anagnostou T; Besser MJ; Batlevi CL; Dahi PB; Devlin SM; Fingrut WB; Giralt SA; Lin RJ; Markel G; Salles G; Sauter CS; Scordo M; Shah GL; Shah N; Scherz-Shouval R; van den Brink M; Perales MA; Palomba ML
J Clin Oncol; 2022 Feb; 40(4):369-381. PubMed ID: 34860572
[TBL] [Abstract][Full Text] [Related]
6. Survival among patients with composite and sequential lymphoma between primary mediastinal lymphoma/diffuse large B-cell lymphoma and classical Hodgkin lymphoma: A population-based study.
Tao Y; Chen H; Liu D; Dai X
Leuk Res; 2021 Dec; 111():106669. PubMed ID: 34333276
[TBL] [Abstract][Full Text] [Related]
7. Outcomes for Relapsed and Refractory Peripheral T-Cell Lymphoma Patients after Front-Line Therapy from the COMPLETE Registry.
Lansigan F; Horwitz SM; Pinter-Brown LC; Rosen ST; Pro B; Hsi ED; Federico M; Gisselbrecht C; Schwartz M; Bellm LA; Acosta M; Shustov AR; Advani RH; Feldman T; Lechowicz MJ; Smith SM; Tulpule A; Craig MD; Greer JP; Kahl BS; Leach JW; Morganstein N; Casulo C; Park SI; Foss FM
Acta Haematol; 2020; 143(1):40-50. PubMed ID: 31315113
[TBL] [Abstract][Full Text] [Related]
8. Relapsed/Refractory International Prognostic Index (R/R-IPI): An international prognostic calculator for relapsed/refractory diffuse large B-cell lymphoma.
Maurer MJ; Jakobsen LH; Mwangi R; Schmitz N; Farooq U; Flowers CR; de Nully Brown P; Thompson CA; Frederiksen H; Cunningham D; Jørgensen J; Poeschel V; Nowakowski G; Seymour JF; Merli F; Haioun C; Ghesquieres H; Ziepert M; Tilly H; Salles G; Shi Q; El-Galaly TC; Habermann TM
Am J Hematol; 2021 May; 96(5):599-605. PubMed ID: 33661547
[TBL] [Abstract][Full Text] [Related]
9. Plain language summary of the TRANSFORM study primary analysis results: lisocabtagene maraleucel as a second treatment regimen for large B-cell lymphoma following failure of the first treatment regimen.
Abramson JS; Solomon SR; Arnason J; Johnston PB; Glass B; Bachanova V; Ibrahimi S; Mielke S; Mutsaers P; Hernandez-Ilizaliturri F; Izutsu K; Morschhauser F; Lunning M; Crotta A; Montheard S; Previtali A; Ogasawara K; Kamdar M
Future Oncol; 2024 Mar; ():. PubMed ID: 38547003
[TBL] [Abstract][Full Text] [Related]
10. Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial.
Kamdar M; Solomon SR; Arnason J; Johnston PB; Glass B; Bachanova V; Ibrahimi S; Mielke S; Mutsaers P; Hernandez-Ilizaliturri F; Izutsu K; Morschhauser F; Lunning M; Maloney DG; Crotta A; Montheard S; Previtali A; Stepan L; Ogasawara K; Mack T; Abramson JS;
Lancet; 2022 Jun; 399(10343):2294-2308. PubMed ID: 35717989
[TBL] [Abstract][Full Text] [Related]
11. Outcomes in patients with aggressive B-cell non-Hodgkin lymphoma after intensive frontline treatment failure.
Ayers EC; Li S; Medeiros LJ; Bond DA; Maddocks KJ; Torka P; Mier Hicks A; Curry M; Wagner-Johnston ND; Karmali R; Behdad A; Fakhri B; Kahl BS; Churnetski MC; Cohen JB; Reddy NM; Modi D; Ramchandren R; Howlett C; Leslie LA; Cytryn S; Diefenbach CS; Faramand R; Chavez JC; Olszewski AJ; Liu Y; Barta SK; Mukhija D; Hill BT; Ma H; Amengual JE; Nathan S; Assouline SE; Orellana-Noia VM; Portell CA; Chandar A; David KA; Giri A; Hess BT; Landsburg DJ
Cancer; 2020 Jan; 126(2):293-303. PubMed ID: 31568564
[TBL] [Abstract][Full Text] [Related]
12. Clinical heterogeneity of diffuse large B cell lymphoma following failure of front-line immunochemotherapy.
Farooq U; Maurer MJ; Thompson CA; Thanarajasingam G; Inwards DJ; Micallef I; Macon W; Syrbu S; Lin T; Lin Y; Ansell SM; Nowakowski GS; Habermann TM; Cerhan JR; Link BK
Br J Haematol; 2017 Oct; 179(1):50-60. PubMed ID: 28653407
[TBL] [Abstract][Full Text] [Related]
13. Burden of Illness and Treatment Patterns in Second-line Large B-cell Lymphoma.
Snider JT; McMorrow D; Song X; Diakun D; Wade SW; Cheng P
Clin Ther; 2022 Apr; 44(4):521-538. PubMed ID: 35241295
[TBL] [Abstract][Full Text] [Related]
14. Prognosis of patients with diffuse large B cell lymphoma not reaching complete response or relapsing after frontline chemotherapy or immunochemotherapy.
Rovira J; Valera A; Colomo L; Setoain X; Rodríguez S; Martínez-Trillos A; Giné E; Dlouhy I; Magnano L; Gaya A; Martínez D; Martínez A; Campo E; López-Guillermo A
Ann Hematol; 2015 May; 94(5):803-12. PubMed ID: 25501975
[TBL] [Abstract][Full Text] [Related]
15. Dynamic monitoring of circulating tumor DNA reveals outcomes and genomic alterations in patients with relapsed or refractory large B-cell lymphoma undergoing CAR T-cell therapy.
Zou H; Liu W; Wang X; Wang Y; Wang C; Qiu C; Liu H; Shan D; Xie T; Huang W; Sui W; Yi S; An G; Xu Y; Ma T; Wang J; Qiu L; Zou D
J Immunother Cancer; 2024 Mar; 12(3):. PubMed ID: 38443094
[TBL] [Abstract][Full Text] [Related]
16. Treatment patterns and outcomes of patients with relapsed or refractory follicular lymphoma receiving three or more lines of systemic therapy (LEO CReWE): a multicentre cohort study.
Casulo C; Larson MC; Lunde JJ; Habermann TM; Lossos IS; Wang Y; Nastoupil LJ; Strouse C; Chihara D; Martin P; Cohen JB; Kahl BS; Burack WR; Koff JL; Mun Y; Masaquel A; Wu M; Wei MC; Shewade A; Li J; Cerhan J; Flowers CR; Link BK; Maurer MJ
Lancet Haematol; 2022 Apr; 9(4):e289-e300. PubMed ID: 35358443
[TBL] [Abstract][Full Text] [Related]
17. Combinational therapy of CAR T-cell and HDT/ASCT demonstrates impressive clinical efficacy and improved CAR T-cell behavior in relapsed/refractory large B-cell lymphoma.
Liu W; Liu W; Zou H; Chen L; Huang W; Lv R; Xu Y; Liu H; Shi Y; Wang K; Wang Y; Xiong W; Deng S; Yi S; Sui W; Peng G; Ma Y; Wang H; Lv L; Wang J; Wei J; Qiu L; Zheng W; Zou D
J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38631712
[TBL] [Abstract][Full Text] [Related]
18. [Clinical Characteristics and Prognosis of 56 Lymphoma Patients with Mediastinal Masses].
Yu H; Wang L; Zhu HY; Wu W; Liang JH; Yin H; Fan L; Li JY; Xu W
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Apr; 28(2):495-499. PubMed ID: 32319385
[TBL] [Abstract][Full Text] [Related]
19. Outcome of Primary Mediastinal Large B Cell Lymphoma Treated with RCHOP.
Halahleh K; Yaseen A; Muradi I; Al-Ibraheem A; Sultan I; Ma'koseh M
J Blood Med; 2023; 14():147-157. PubMed ID: 36846350
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
